Yubo International Biotech Ltd. Files 2023 Annual Report

TL;DR

<b>Yubo International Biotech Ltd. has filed its annual 10-K report for the fiscal year ending December 31, 2023.</b>

AI Summary

Yubo International Biotech Ltd (YBGJ) filed a Annual Report (10-K) with the SEC on April 12, 2024. Yubo International Biotech Ltd. filed its 10-K report for the fiscal year ending December 31, 2023. The company's primary business address is located in Beijing, China. Yubo International Biotech Ltd. was formerly known as MAGNA LAB INC, with a name change on July 22, 1994. The company is incorporated in New York. The filing covers the period from January 1, 2023, to December 31, 2023.

Why It Matters

For investors and stakeholders tracking Yubo International Biotech Ltd, this filing contains several important signals. This filing provides a comprehensive overview of the company's financial performance and operational status for the past fiscal year. As a public document, it offers transparency to investors and stakeholders regarding the company's business, risks, and financial health.

Risk Assessment

Risk Level: — Yubo International Biotech Ltd shows moderate risk based on this filing. The filing is a standard annual report (10-K) with no immediate red flags or significant negative disclosures, indicating a routine update.

Analyst Insight

Review the detailed financial statements and risk factors within the 10-K filing to understand Yubo International Biotech Ltd.'s current financial position and future outlook.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 1994-07-22 — Date of Name Change (Former company name)
• 2024-04-12 — Filing Date (Date of submission)

Key Players & Entities

• Yubo International Biotech Ltd. (company) — Filer name
• MAGNA LAB INC (company) — Former company name
• New York (location) — State of incorporation
• Beijing (location) — Business address city

FAQ

Industry Context

Yubo International Biotech Ltd. operates within the electromedical and electrotherapeutic apparatus industry.

Regulatory Implications

The company is subject to SEC regulations for public companies, including the requirement to file annual reports (10-K).

What Investors Should Do

1. Analyze the financial statements for revenue, net income, and other key metrics.
2. Review the 'Risk Factors' section for potential business challenges and uncertainties.
3. Examine management's discussion and analysis (MD&A) for insights into operational performance and strategy.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-04-12: Filing Date — Date the 10-K report was officially submitted to the SEC.

Year-Over-Year Comparison

This is the company's annual 10-K filing for the fiscal year 2023, providing updated information compared to previous filings.

Key Financial Figures

• $0.001 — Act: Class A common stock, par value $0.001 per share (Title of Class) Indicate

Filing Documents

• yubo_10k.htm (10-K) — 1108KB
• yubo_ex101.htm (EX-10.1) — 51KB
• yubo_ex102.htm (EX-10.2) — 51KB
• yubo_ex103.htm (EX-10.3) — 51KB
• yubo_ex311.htm (EX-31.1) — 12KB
• yubo_ex312.htm (EX-31.2) — 9KB
• yubo_ex321.htm (EX-32.1) — 4KB
• yubo_ex322.htm (EX-32.2) — 4KB
• yubo_10kimg1.jpg (GRAPHIC) — 20KB
• 0001640334-24-000618.txt (&nbsp;) — 5058KB
• yubo-20231231.xsd (EX-101.SCH) — 53KB
• yubo-20231231_lab.xml (EX-101.LAB) — 269KB
• yubo-20231231_cal.xml (EX-101.CAL) — 47KB
• yubo-20231231_pre.xml (EX-101.PRE) — 244KB
• yubo-20231231_def.xml (EX-101.DEF) — 149KB
• yubo_10k_htm.xml (XML) — 651KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 7 Item 1B. Unresolved Staff Comments 31 Item 2.

Properties

Properties 32 Item 3.

Legal Proceedings

Legal Proceedings 32 Item 4. Mine Safety Disclosures 32 PART II 33 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 33 Item 6. [Reserved] 35 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 39 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 40 Item 9. Changes in and Disagreement with Accountants on Accounting and Financial Disclosure 41 Item 9A.

Controls and Procedures

Controls and Procedures 41 Item 9B. Other Information 41 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 41 PART III 42 Item 10. Directors, Executive Officers and Corporate Governance 42 Item 11.

Executive Compensation

Executive Compensation 44 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 45 Item 13. Certain Relationships and Related Transactions, and Director Independence 47 Item 14. Principal Accountant Fees and Services 48 PART IV 49 Item 15. Exhibits, Financial Statement Schedules 49 Item 16. Form 10-K Summary 49 i Table of Contents the results of Yubo Beijing's (as defined herein) research and development activities relating, in particular, to stem cell related technologies; the early stage of Yubo Beijing's product candidates presently under development; the need for substantial additional funds in order to continue our operations, and the uncertainty of whether we will be able to obtain the funding we need; Yubo Beijing's ability to obtain and, if obtained, maintain regulatory approval of its current product candidates, and any of its other future product candidates, and any related restrictions, limitations, and/or warnings in the label

Business

Item 1. Business. In this Annual Report, unless otherwise specified, the terms "we," "our," "us," the "Company," or the "Registrant" refer to Yubo International Biotech Limited, a U.S. holding company and New York corporation, formerly known as Magna-Lab, Inc., and its wholly owned subsidiaries, including without limitation, Platinum International Biotech Co., Ltd., a company organized under the laws of the Cayman Islands ("Platinum"), Platinum International Biotech (Hong Kong) Limited, a company organized under the laws of Hong Kong ("Platinum HK"), and Yubo International Biotech (Chengdu) Limited, a company organized under the laws of the People's Republic of China ("Yubo Chengdu" or the "WFOE"). The term "Yubo Beijing" refers to Yubo International Biotech (Beijing) Limited, a variable interest entity organized under the laws of the People's Republic of China, and, through contractual arrangements with, the Chinese operating company. Corporate Overview We are a U.S. holding company primarily operating through our wholly owned subsidiary, Platinum. Platinum is not a Chinese operating company but a Cayman Islands holding company which in turn operates in China through its subsidiaries and contractual arrangements with Yubo Beijing, the Chinese operating company. None of our Company, Platinum, or Platinum HK, each as a holding company, conducts any day-to-day business operations in China. Yubo Beijing conducts the day-to-day business operations of our Company in China through contractual relationships with us. Yubo Beijing is a technology company focused on the research and development and application of endometrial stem cells. Yubo Beijing is committed to building the first public endometrial stem cell repository in the world. Yubo Beijing offers its products and services under the brand "VIVCELL." Yubo Beijing's product offerings include healthcare products for respiratory system, skincare products, hair care products, healthy beverages and male and female p

View Full Filing

View this 10-K filing on SEC EDGAR